EU Medicines Agency Panel Issues Positive Opinion on SFL Pharmaceuticals' Lung Cancer Drug Aumseqa

06:36 AM EST, 11/13/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of SFL Pharmaceuticals Deutschland's Aumseqa for non-small cell lung cancer, or NSCLC. Aumseqa, or aumolertinib, improves the progression-free survival of patients with advanced NSCLC, compared with gefitinib monotherapy, according to a Friday notice. It is intended for NSCLC patients whose tumors have EGFR exon 19 deletions or exon 21 substitution mutations, and those with EGFR T790M mutation-positive NSCLC. The drug is subject to final approval from the European Commission.